Ken, you said you thought the FDA granted Fast Track designation in 2019. Good memory. This is from the 10-K for the fiscal year ended 5/31/25.

Quote:

---

In November 2018, the Company received FDA approval of its Investigational New Drug (“IND”) submission and subsequently initiated a Phase 1b/2 clinical trial for mTNBC. In May 2019, the FDA granted Fast Track designation for leronlimab for use in combination with carboplatin to treat patients with CCR5+ positive mTNBC.

---